TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05554978
Drug: Landiolol
Normalized name: Landiolol
DrugBank: Landiolol (DB12212)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: patient receives landiolol in addition to standard-of-care
Study: NCT05554978
Drug: Sodium Chloride (NaCl) 0.9%
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo
Study: NCT05783921
Drug: TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TQB2618 injection is an Anti TIM-3 (T-cell immunoglobulin and mucin domain-3) monoclonal antibody.~Penpulimab injection is a humanized Monoclonal Antibody target Programmed Cell Death Protein 1 (PD-1).~Paclitaxel is a anti-microtubule drug, which promotes tubulin polymerization, inhibits depolymerization, maintains tubulin stability and inhibits cell mitosis.~Cisplatin inhibits DNA synthesis by generating in-strand interstrand crosslinking with DNA. Protein and RNA synthesis can also be inhibited.~Carboplatin is a cyclic nonspecific antitumor agents that cause cross-linking between DNA strands and affect their synthesis to inhibit cancer cells.
Study: NCT05783921
Drug: Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penpulimab injection is a humanized Monoclonal Antibody target Programmed Cell Death Protein 1 (PD-1).~Paclitaxel is a anti-microtubule drug, which promotes tubulin polymerization, inhibits depolymerization, maintains tubulin stability and inhibits cell mitosis.~Cisplatin inhibits DNA synthesis by generating in-strand interstrand crosslinking with DNA. Protein and RNA synthesis can also be inhibited.~Carboplatin is a cyclic nonspecific antitumor agents that cause cross-linking between DNA strands and affect their synthesis to inhibit cancer cells.
Study: NCT04879849
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion.
Study: NCT04879849
Drug: TAK-676
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion.
Study: NCT05043519
Drug: FAM-NP41
Normalized name: fam-trastuzumab deruxtecan-nxki
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The patients will be injected with FAM-NP41 in one dose intravenously 2 hours prior to the dural incision.
Study: NCT05535738
Drug: Squaric Acid Dibutyl Ester
Normalized name: Squaric acid dibutyl ester
DrugBank: Squaric acid dibutyl ester (DB12223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensitization dose: 2% Elicitation doses: {0.0001%, 0.00025%, 0.00075%, 0.001%, 0.0025%, 0.005%, 0.0075%, 0.01%, 0.025%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6% 0.7%, 0.8%, 0.9%, 1.0%, 1.2%, 1.4%, 1.6%, 1.8%, 2.0%}
Study: NCT05535738
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300mg
Study: NCT05535738
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 40mg
Study: NCT05535738
Drug: Ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 45mg
Study: NCT05535738
Drug: Guselkumab
Normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100mg
Study: NCT05535738
Drug: Canakinumab
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150mg
Study: NCT05535738
Drug: Sarilumab
Normalized name: Sarilumab
DrugBank: Sarilumab (DB11767)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg
Study: NCT05535738
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1% ointment
Study: NCT05535738
Drug: Betamethasone Valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1% ointment
Study: NCT05535738
Drug: Fluticasone Propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.005% ointment
Study: NCT05320159
Drug: Secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Included all the patients treated with secukinumab
Study: NCT05008731
Drug: Botulinum toxin
Normalized name: Botulinum toxin
DrugBank: Botulinum toxin type B (DB00042)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 units (0.5ml) in 1 injection
Study: NCT04839471
Drug: BI-754091 plus afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eligible patients will receive BI-754091 240 mg on D1, afatinib 30 mg/day on day 1 to 21 in a 3-week cycle.
Study: NCT04583254
Drug: Concurrent Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly cisplatin 40 mg/m2 for a maximum of 5 cycles
Study: NCT04909502
Drug: EHP-101 25 mg OD
Normalized name: EHP-102
DrugBank: EHP-102 (DB16933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg OD during the first 28 Days of the trial
Study: NCT04909502
Drug: EHP-101 25 mg BID
Normalized name: EHP-102
DrugBank: EHP-102 (DB16933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg BID during the first 28 Days of the trial
Study: NCT04909502
Drug: EHP-101 50 mg OD
Normalized name: EHP-102
DrugBank: EHP-102 (DB16933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 28 Days of treatment with 25 mg OD, patients will escalate to 50 mg OD up to the end of the trial
Study: NCT04909502
Drug: EHP-101 50 mg BID
Normalized name: EHP-102
DrugBank: EHP-102 (DB16933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 28 Days of treatment with 25 mg BID, patients will escalate to 50 mg BID up to the end of the trial
Study: NCT04287803
Drug: Methoxyflurane
Normalized name: Methoxyflurane
DrugBank: Methoxyflurane (DB01028)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methoxyflurane 3mls will be self administered by patients meeting the inclusion criteria with acute traumatic pain scores \>=4
Study: NCT05586958
Drug: Tigulixostat
Normalized name: Tigulixostat
DrugBank: Tigulixostat (DB18799)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanthine Oxidase Inhibitor
Study: NCT04883528
Drug: Sacubitril / Valsartan Oral Tablet [Entresto]
Normalized name: sacubitril / valsartan Oral Tablet [Entresto]
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
Study: NCT04831528
Drug: Cetuximab Ab; Bevacizumab; Vermofenib + cetuximab;Trastuzumab+lapatinib or trastuzumab+pertuzumab; others
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After PD, patients received ctDNA testing, and different research protocols were selected according to different gene states of ctDNA, as follows: 1.No secondary changes related to drug resistance were found. Cetuximab cross-line + second-line chemotherapy (FOLFOX/FOLFIRI/ Irinotecan monotherapy, etc.) was used.2. If there is a RAS secondary mutation, change of beacizumab bead sheet resistance + second-line chemotherapy (FOLFOX/XELOX/stand for kang single-agent FOLFIRI mXEIRI/Iraq, etc.);3. If BRAF secondary mutation occurs, replace it with vimofenib + cetuximab + irinotecan;4. If HER2 amplification occurs, replace it with trastuzumab + lapatinib or trastuzumab + pertuzumab;5. In case of other secondary mutations, bevacizumab plus second-line chemotherapy should be replaced.
Study: NCT06360081
Drug: Zongertinib
Normalized name: Zongertinib
DrugBank: Zongertinib (DB18762)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zongertinib
Study: NCT00041171
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05981937
Drug: ICG solution
Normalized name: ICG-136
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICG-ATT is available at our institute since 2019 using a near-infrared (NIR) light source and special scope and camera equipped with xenon light (CARL STORZ GmbH \& Co. KG, Tuttlingen, Germany); ICG was supplied as a sterile water-soluble lyophilized powder (Diagnostic Green® GmbH). ICG-ATT is routinely used whenever available in daily practice with the following protocol: after the specimen resection the two colonic stumps or colonic and rectal stumps are checked with 5 cc of ICG 25 mg diluted in 10 cc of water sterile solution before fashioned anastomosis. Two laparoscopes with ICG-optic system are nowadays available department and ICG anastomosis control is always performed if ICG device are available (no performed in case of not available ICG instrument for sterilization in case of two consecutive surgery in the same day, concomitant ICG surgery or ICG malfunction).
Study: NCT06508684
Drug: BTK inhibitor
Normalized name: BTK inhibitor CC-292
DrugBank: Spebrutinib (DB11764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTKi can refer to Orelabrutinib, Ibrutinib, Zanubrutinib, and Acalabrutinib
Study: NCT05625373
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The powder will be placed within the surgical wound prior to skin closure.
Study: NCT06508931
Drug: zamtocabtagene autoleucel (MB-CART2019.1)
Normalized name: Brexucabtagene autoleucel
DrugBank: Zamtocabtagene autoleucel (DB18764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy.
Study: NCT05497492
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single administration of propofol
Study: NCT05497492
Drug: propofol and esketamine
Normalized name: esketamine
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: administration of propofol and esketamine in combination
Study: NCT05497492
Drug: propofol and lidocaine
Normalized name: Propofol
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administration of propofol and lidocaine in combination
Study: NCT05764668
Drug: Zihua Wenfei Zhisou Granule
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14 daily- doses of Zihua Wenfei Zhisou Granule，one bag at a time (15 g/bag), three times/day
Study: NCT04859244
Drug: GS-441524
Normalized name: GS-441524
DrugBank: GS-441524 (DB15686)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg administered as a solution
Study: NCT05424263
Drug: Calcium Carbonate Oral Suspension
Normalized name: Calcium Carbonate Oral Suspension
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be supplemented with calcium carbonate (2,500 mg/day), as described in the arm/group descriptions, for 12 weeks.
Study: NCT04104919
Drug: Brivoligide Injection 660 mg/6 mL
Normalized name: Brivoligide
DrugBank: Brivoligide (DB16116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative intrathecal injection
Study: NCT04962230
Drug: PF-07321332/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PF-07321332/ritonavir administered orally as a single dose on Day 1, Period 1
Study: NCT04962230
Drug: Carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In Period 2, Days 1-3, participants will receive low-dose of carbamazepine twice daily (BID), then a titrated mid-dose of carbamazepine BID on Days 4-7, and finally maintaining carbamazepine at the high-dose on Days 8-15.
Study: NCT04962230
Drug: PF 07321332/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In Period 2, Day 14, participants will receive a single dose of PF-07321332/ritonavir orally.
Study: NCT05361499
Drug: Amoxicillin 500 mg
Normalized name: amoxicillin 500 MG
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin, 7 days, 2x 500 mg
Study: NCT05551013
Drug: APG-157
Normalized name: APG-157
DrugBank: APG-157 (DB18683)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APG-157 is an orally administered drug encased in a hydrogel pastille.~Arms:~* Ongoing Stupp protocol (will receive concurrent TMZ + APG-157)~* Progression post TMZ (will receive APG-157 only)~* Ongoing Optune (will receive concurrent Optune + APG-157)~* Progression post Optune (will receive APG-157 only)
Study: NCT05962034
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 650 mg aspirin (Acetylsalicylic acid)
Study: NCT05037487
Drug: Placebo Cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoked placebo cannabis
Study: NCT05037487
Drug: 20 mg CBD Cannabis
Normalized name: Cannabis indica top
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoked cannabis with CBD
Study: NCT05037487
Drug: 20 mg CBD + 20 mg THC Cannabis
Normalized name: Cannabis indica top
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoked cannabis with CBD and THC
Study: NCT05037487
Drug: 20 mg THC Cannabis
Normalized name: Cannabis indica top
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoked cannabis with THC
Study: NCT05938920
Drug: INS018_055
Normalized name: INS018_055
DrugBank: INS018_055 (DB18083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical formulation: Capsules~Mode of Administration: Oral
Study: NCT05540834
Drug: Alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The enzyme tissue plasminogen activator that cleaves plasminogen to form plasmin.
Study: NCT04832139
Drug: Marstacimab PFP
Normalized name: Marstacimab
DrugBank: Marstacimab (DB17725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 milligrams (mg) subcutaneous injection marstacimab PFP
Study: NCT04832139
Drug: Marstacimab PFS
Normalized name: Marstacimab
DrugBank: Marstacimab (DB17725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg subcutaneous injection of marstacimab PFS
Study: NCT05149131
Drug: ADT (Eligard®*) with or without treatment intensification
Normalized name: E-Z Scrub with Ultradex Medicated Pad or Tape
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abiraterone acetate (Zytiga®) Enzalutamide (Xtandi®) Apalutamide (Erleada®) Docetaxel (Taxotere®)~\*may be substituted with leuroprolide gel, buserelin, goserelin, triptorelin, histrelin, cyproterone or degarelix
Study: NCT00002039
Drug: Foscarnet sodium
Normalized name: Foscarnet Sodium
DrugBank: Foscarnet (DB00529)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05330858
Drug: Rabeprazole
Normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT05463068
Drug: NVX-Cov2373
Normalized name: NVX-CoV2373
DrugBank: Nuvaxovid (DB15810)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL) on Day 1
Study: NCT04702906
Drug: trimetazidine hydrochloride metacardia ® 20 mg tablet
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimetazidine hydrochloride metacardia ® (20 mg three times daily produced by Global NAPI Pharmaceuticals-Egypt)
Study: NCT06254664
Drug: Tiotropium 18 µg inhalation powder, hard capsule
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 µg administered using Zephir inhaler
Study: NCT06378645
Drug: General Anesthesia: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transurethral surgery at the Department of Urology (University Hospital Zurich) performed under study arm-specific anesthesia.~Propofol will be administered intravenously using the target-controlled infusion algorithm with effect site concentrations between 1.5-4.0 µg/ml necessary.
Study: NCT06378645
Drug: General Anesthesia: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transurethral surgery at the Department of Urology (University Hospital Zurich) performed under study arm-specific anesthesia.~Sevoflurane will be given in gaseous form via the endotracheal tube in concentrations between 1.5-2.5% Vol.
Study: NCT05675761
Drug: Azorubine
Normalized name: Azaribine
DrugBank: Azaribine (DB19364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azovudine tablets, 1mg /tablet, 5 tablets, QD+basic treatment (14 days at most)
Study: NCT00000916
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000916
Drug: Lamivudine/Zidovudine
Normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000916
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000916
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00000916
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000916
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000916
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06334757
Drug: Serplulimab
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg，IV，Q3W
Study: NCT06334757
Drug: Bevacizumab Biosimilar HLX04
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 7.5 mg/kg，Q3W
Study: NCT06334757
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/m2，IV，Q3W
Study: NCT06334757
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC=5，IV，Q3W
Study: NCT05209308
Drug: Zandelisib
Normalized name: Zandelisib
DrugBank: Zandelisib (DB18245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zandelisib taken orally for 7 days of each 28 day cycle
Study: NCT05209308
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab IV for 6 cycles
Study: NCT05209308
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Orally - Ramp up weeks 1-5
Study: NCT06233864
Drug: Disitamab Vedotin
Normalized name: Disitamab vedotin
DrugBank: Disitamab vedotin (DB17208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disitamab Vedotin
Study: NCT06233864
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine
Study: NCT05512702
Drug: Tissue Plasminogen Activator, Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose (50 mg) Alteplase is used for the patients in the thrombolytic treatment group.
Study: NCT06030492
Drug: packing placental site with hydrogen peroxide soaked towels
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Skin is incised either midline or Pfannenstiel incision according to clinical situation , bladder dissection will be done , uterus will be incised by transverse lower segment incision , followed by delivery of the baby.~Uterine massage , ecbolics \& a trial for delivery of the placenta will be done Irrigation of the placental bed with 100 ml 3% hydrogen peroxide , followed by packing with a towel highly soaked hydrogen peroxide solution (Pozitif Kimya, İstanbul, Turkey) , freshly prepared by a 50% dilution with a normal saline solution
Study: NCT05020964
Drug: Trastuzumab and Pyrotinib
Normalized name: pertuzumab and trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab: 3-week dosing regimen, The initial load dose was 8 mg/kg. Pyrotinib: 400 mg orally once daily, take it continuously, every 21 days as a cycle.~Use until intolerable toxicity or disease progression occurs.
Study: NCT05777122
Drug: lignocaine gel
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pharmacological ,topical anesthetic gel
Study: NCT06279793
Drug: Long-chain n-3 fatty acids
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omegaven® is a 10% fish oil emulsion supplement with a high percentage of long-chain n-3 fatty acids - mainly eicosapentaenoic acid and docosahexaenoic acid. It is a lipid emulsion supplement that optimises the fatty acid pattern in parenteral nutrition and is a source of polyunsaturated n-3 fatty acids as cell membrane components and precursors for eicosanoids.~Omegaven® is manufactured by Fresenius-Kabi, Germany and is available in 100 mL bottles for study purpose.~Each 100 mL of Omegaven® contains 10 g of fish oil (0.1 g/mL).~Timeframe:~Day -1: 0.20 g fish oil/kg BW/d; the treatment should be started 24 to 3 h before surgery, can be given as 3-6 hours infusion.~Intraoperative Day: No dose~Post OP (Day 0): 0.20 g fish oil/kg BW/d~Post OP ( Day 1 to max Day 7): 0.20 g fish oil/kg BW/d
Study: NCT06279793
Drug: Intravenous 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous 0.9% Sodium Chloride (volume 2 mL/kg BW/d)
Study: NCT01061047
Drug: Ertapeneme
DrugBank: Ertapenem (DB00303)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05278364
Drug: SY-5007
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a RET selective Inhibitor
Study: NCT05110469
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Magnesium sulphate 30 mg/kg, labeled as research drug for blinding, were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression.
Study: NCT05110469
Drug: Meperidine
Normalized name: Meperidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Meperidine 0.5 mg/kg, labeled as research drug for blinding, were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression.
Study: NCT00596115
Drug: R(+) pramipexole dihydrochloride monohydrate
Normalized name: Pramipexole Dihydrochloride
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg tid per day orally
Study: NCT00344734
Drug: Ng-monomethyl-L-arginine (drug)
Normalized name: NG-Monomethyl-L-arginine
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no